A Randomized, Double-Blind, Double-Dummy, Single-Dose, Crossover Trial Evaluating the Efficacy and Safety Profiles of Two Dose Levels (12 and 24 μg) of Formoterol-HFA (pMDI) vs. Those of a Dose Level (24 μg) of Formoterol-DPI (Foradil^®/Aerolizer^™) and of Placebo (pMDI or Aerolizer) in Moderate to Severe Asthmatic Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 13-19

Karger

Access to resources Recommend Favorite

A Randomized, Double-Blind, Double-Dummy, Safety Crossover Trial Comparing Cumulative Doses up to 96 μg of Formoterol Delivered via an HFA-134a-Propelled pMDI vs. Same Cumulative Doses of Formoterol DPI and Placebo in Asthmatic Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 28-34

Karger

Access to resources Recommend Favorite

Bronchoprotective and Bronchodilator Effects of an HFA pMDI vs. a CFC pMDI and a DPI Containing Formoterol in Asthma Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 35-37

Karger

Access to resources Recommend Favorite

Double-Blind, Double-Dummy, Multinational, Multicenter, Parallel-Group Design Clinical Trial of Clinical Non-Inferiority of Formoterol 12 μg/Unit Dose in a b.i.d. Regimen Administered via an HFA-Propellant-pMDI or a Dry Powder Inhaler in a 12-Week Treatment Period of Moderate to Severe Stable Persistent Asthma in Adult Patients

By  

Respiration, Vol. 72, Iss. 1, 2005-05 ,pp. : 20-27

Karger

Access to resources Recommend Favorite

Budget Impact Analysis of a Fixed-Dose Combination of Fluticasone Propionate and Formoterol Fumarate (FP/FORM) in a Pressurized Metered-Dose Inhaler (pMDI) for Asthma

By Dunlop William   Heron Louise   Fox Georgia   Greaney Maire  

Advances in Therapy, Vol. 30, Iss. 10, 2013-10 ,pp. : 933-944

Springer Publishing Company

Access to resources Recommend Favorite